Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opko Health has acquired exclusive worldwide rights in the field of ophthalmology to a novel small molecule agent in Phase II clinical development for the treatment of viral conjunctivitis and other viral infections.
Subscribe to our email newsletter
The agent, CTC-96, also known as Doxovir, was developed by Redox Pharmaceutical. CTC-96’s novel antiviral mechanism has demonstrated efficacy against multiple viral infections in preclinical studies. CTC-96 has anti-inflammatory properties but it is a nonsteroidal compound, an important safety advantage for an ocular drug.
Samuel Reich, executive vice president of ophthalmics at Opko, said: “We look forward to initiating Phase II trials assessing CTC-96 for the treatment of viral conjunctivitis in the coming months.”